【摘要】 目的 探讨八宝丹联合米拉贝隆治疗伴Ⅲ型前列腺炎膀胱过度活动症(overactive bladder,OAB)的临床效果。方法 选取2021年10月至2023年1月山东第一医科大学附属山东省立医院收治的60例伴Ⅲ型前列腺炎膀胱过度活动症患者作为研究对象,按照随机数字表法分为试验组(n=30,给予八宝丹和米拉贝隆联合治疗)与对照组(n=30,给予米拉贝隆治疗),两组均持续治疗12周。比较两组治疗前后膀胱过度活动症评分(overactive bladder syndrome score,OABSS)、生命质量量表(quality of life,QOL)评分、国际前列腺症状评分(International Prostate Symptom Score,IPSS)、临床疗效及不良反应发生情况。结果 两组治疗前OABSS、QOL评分、IPSS比较,差异均无统计学意义(P>0.05)。治疗后4、12周,试验组OABSS均低于对照组,差异有统计学意义(P<0.05)。治疗后,两组QOL评分均低于治疗前,且试验组低于对照组,差异有统计学意义(P<0.05)。治疗后4、12周,两组IPSS均低于治疗前,且试验组低于对照组,差异有统计学意义(P<0.05)。试验组治疗总有效率(86.67%)高于对照组(66.67%),差异无统计学意义(P>0.05)。两组均未出现明显不良反应。结论 采用八宝丹联合米拉贝隆治疗伴Ⅲ型前列腺炎OAB具有优势,可减轻患者临床症状,降低痛苦程度,提高生命质量、临床疗效,且无明显不良反应发生。更多还原

【Abstract】 Objective To assess the clinical efficacy of combining Babaodan with Milabelon in the treatment of overactive bladder with type Ⅲ prostatitis.Methods A total of 60 patients diagnosed with overactive bladder with type Ⅲ prostatitis at Shandong Provincial Hospital Affiliated to Shandong First Medical University between October 2021 and January 2023 were enrolled.Patients were randomly assigned to either the experimental group(n=30,received a combination of Babaodan and Milabelon) or control group(n=30,received Milabelon treatment).Both groups underwent a continuous 12-week treatment regimen.The overactive bladder syndrome score(OABSS),quality of life(QOL) score,International Prostate Symptom Score(IPSS),clinical efficacy,and adverse reaction incidence were compared before and after treatment in both groups.Results Before treatment,there rvere no significant differences in OABSS,QOL and IPSS between the two groups(P>0.05).However,at 4 weeks and 12 weeks after treatment,the OABSS scores of the experimental group were lower than those of the control group,the difference were statistically significant(P<0.05).After treatment,the QOL scores of both groups were lower than those before treatment,and the experimental group was lower than the control group,the difference was statistically significant(P<0.05).At 4 weeks and 12 weeks after treatment,the IPSS scores of the two groups were lower that before treatment,and the IPSS scores of the experimental group were lower than those of the control group,the difference were statistically significant(P<0.05).Moreover,the experimental group demonstrated a higher total effective treatment rate,although this difference was not statistically significant(P>0.05).There were no obvious adverse reactions in both groups.Conclusions The combined use of Babaodan and Milabelon represents a promising therapeutic approach for the treatment of OAB with type Ⅲ prostatitis.This treatment can significantly alleviate clinical symptoms,enhance quality of life,and improve clinical outcomes without notable adverse effects.更多还原